'Favorable' Long-Term Survival Associated with Up-Front Liver Resection and Postsurgical Chemotherapy for Metastatic Colorectal Cancer

Share this article:
(ChemotherapyAdvisor) – Resection of metastatic colorectal cancer (mCRC) liver tumors followed by adjuvant chemotherapy leads to “good clinical outcomes,” report authors of a retrospective single-institution Canadian study published in the Annals of Surgical Oncology.

“Up-front surgery for patients with resectable CRC liver metastases, followed by chemotherapy, can lead to favorable OS,” reported a team led by Sulaiman Nanji, MD, PhD, of the Department of Surgery at Queen's University, in Kingston, Ontario, Canada.

Combined surgery and chemotherapy is the standard of care for metastatic CRC, but there is not yet consensus about the optimal timing or sequence of liver resection and chemotherapy, the authors wrote.

They performed a retrospective records review of patients who had undergone liver resection from 2002 to 2007 at the largest-volume mCRC liver resection-performing institution in Canada, where patients with resectable hepatic metastases are offered up-front surgery followed by adjuvant 5-fluorouracil-based or capecitabine-based chemotherapy. Of 320 patients, 36 (11%) received preoperative chemotherapy to downstage unresectable disease.

“Actual disease-free survival at 3 and 5 years was 46.2% and 42%, respectively,” Dr. Nanji and coauthors wrote. “Actual overall survival at 3 and 5 years was 63.7% and 55%, respectively.”

Median OS was 35.1 months, the authors reported. Larger metastases (>6 cm), positive lymph node status, synchronous disease at presentation (the presence of hepatic metastases detected before or at the same time as resection of primary colorectal tumors), and absence of postoperative chemotherapy were all significantly associated with poorer OS after multivariate analysis, the authors reported. No association was found between OS and the number of metastatic tumors.

"There was a significant survival advantage in patients who received both postprimary and posthepatectomy chemotherapy (P = 0.041)" over patients who received chemotherapy only for their primary CRC tumors, the authors wrote. 

Randomized trials are needed to “more definitively address the timing of perioperative chemotherapy, in addition to the need for prospectively collected data using validated stratification systems to select the best use of these strategies,” the authors concluded.

Abstract 

Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Gastrointestinal Cancers

Updated Results Announced for ThermoDox Use for HCC

Updated Results Announced for ThermoDox Use for HCC

Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the ...

Combined Tobacco, Alcohol Use Spikes Esophageal Cancer Risk

Combined Tobacco, Alcohol Use Spikes Esophageal Cancer Risk

Rates of esophageal squamous cell carcinoma (ESCC) nearly double for those who use tobacco and consume alcohol, compared to individuals who only smoke or drink.

FDA Approves Cyramza for Gastric Cancer

FDA Approves Cyramza for Gastric Cancer

Eli Lilly and Company announced that the FDA has approved Cyramza (ramucirumab) 10mg/mL injection, for the treatment of patients with advanced or metastatic, gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma, ...